Cheung Leung, MD
Cardiovascular Disease · Gilroy, CANPI 1427083112
Payments from drug & device makers
Across 466 payments — averaging $31.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Pfizer$1K
- Merck$1K
- Johnson & Johnson$856
- Amarin Pharma, Inc.$616
- Abbott$596
- plus $7K from 35 others
What the payments were for
- Speaking & faculty fees$2001%
- Food & beverage$14,11097%
- Education$1811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $2,993 |
| Pfizer | 64 | $1,397 |
| Merck | 34 | $1,028 |
| Johnson & Johnson | 47 | $856 |
| Amarin Pharma, Inc. | 29 | $616 |
| Abbott | 10 | $596 |
| Bayer | 14 | $572 |
| Heartflow, Inc. | 6 | $517 |
| Medtronic(2 entities) | 5 | $492 |
| Novartis | 21 | $459 |
| Sanofi-aventis U.S. LLC | 16 | $454 |
| Esperion Therapeutics, Inc. | 17 | $450 |
| E.r. Squibb & Sons, L.L.C. | 18 | $450 |
| GSK | 9 | $360 |
| Alnylam Pharmaceuticals Inc. | 8 | $336 |
| Boston Scientific | 7 | $315 |
| Boehringer Ingelheim | 28 | $293 |
| Edwards Lifesciences | 4 | $265 |
| Amgen | 4 | $210 |
| Vifor Pharma, Inc. | 1 | $200 |
| Biotronik Inc. | 3 | $198 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $189 |
| AstraZeneca | 4 | $188 |
| Lilly USA, LLC | 6 | $147 |
| Mylan Specialty L.p. | 5 | $108 |
| Baxter Healthcare | 4 | $100 |
| Regeneron Healthcare Solutions, Inc. | 3 | $92 |
| Philips North America LLC | 4 | $92 |
| Seqirus USA Inc | 4 | $87 |
| Kowa Pharmaceuticals America, Inc. | 2 | $61 |
| Corcept Therapeutics | 1 | $59 |
| Irhythm Technologies, Inc. | 2 | $52 |
| AbbVie(2 entities) | 2 | $42 |
| Artivion, Inc. | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 1 | $33 |
| Abiomed | 1 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Medicure Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$963
- FREESTYLE LIBRE 3$397
- Kerendia$352
- FFRct$308
- Micra$258
- Wegovy$238
- Veltassa$200
- Edwards SAPIEN 3 Transcatheter Heart Valve$177
- AMVIA EDGE$143
- Xultophy 100/3.6$125
- VYNDAQEL$125
- NEXLETOL$125
- NEXLIZET$125
- Repatha$125
- RYBELSUS$125
- LOKELMA$125
- Watchman$125
- AMVUTTRA$124
- ARCALYST$124
- VERQUVO$122
How this compares
$14,491 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 131 | $176,204 |
| OzempicSemaglutide | 56 | $66,391 |
| XareltoRivaroxaban | 17 | $25,748 |
| VascepaIcosapent Ethyl | 16 | $16,301 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,574 |
| Ezetimibe | 224 | $6,902 |
| Atorvastatin Calcium | 580 | $6,831 |
| Amlodipine Besylate | 486 | $3,728 |
| Ranolazine ErRanolazine | 19 | $3,478 |
| Rosuvastatin Calcium | 131 | $3,030 |
| Amiodarone Hcl | 92 | $2,951 |
| Potassium Chloride | 122 | $2,118 |
| Carvedilol | 181 | $1,855 |
| Losartan Potassium | 196 | $1,767 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 14 | $1,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,397 | $176,204131 claims |
| Novo NordiskOzempic | $2,993 | $66,39156 claims |
| Johnson & JohnsonXarelto | $856 | $25,74817 claims |
| GSKBreo Ellipta | $360 | $8,57414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Gilroy
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.